-
41.发明申请公开(公告)号：US20190255113A1
公开(公告)日：2019-08-22
申请号：US16376727
申请日：2019-04-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska Hoffgaard , Jens Fritsche , Oliver Schoor , Toni Weinschenk , Daniel Johannes Kowalewski , Chih-Chiang Tsou
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
42.发明申请公开(公告)号：US20250145684A1
公开(公告)日：2025-05-08
申请号：US19015015
申请日：2025-01-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Gisela SCHIMMACK , Annika SONNTAG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Michael ROEMER , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/73 , A61K35/17 , A61K39/00 , C07K7/00 , C07K14/705 , C07K14/74 , C07K16/00 , C12N5/0783
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20250034227A1
公开(公告)日：2025-01-30
申请号：US18785378
申请日：2024-07-26
Applicant: Immatics Biotechnologies GmbH
Inventor： Felix UNVERDORBEN , Sebastian BUNK , Martin HOFMANN , Meike HUTT , Timo MANZ , Nadine ASCHMONEIT , Maike JAWORSKI , Lena SCHMOHL , Claudia WAGNER , Dominik MAURER , Heiko SCHUSTER , Nora TREIBER
IPC: C07K14/725 , A61K38/00 , A61P35/00
Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.
-
公开(公告)号：US20240374640A1
公开(公告)日：2024-11-14
申请号：US18599838
申请日：2024-03-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
45.发明公开公开(公告)号：US20240358756A1
公开(公告)日：2024-10-31
申请号：US18599924
申请日：2024-03-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC classification number: A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
Patent Agency Ranking
46.发明公开公开(公告)号：US20240299455A1
公开(公告)日：2024-09-12
申请号：US18599860
申请日：2024-03-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC classification number: A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
47.发明公开公开(公告)号：US20240269184A1
公开(公告)日：2024-08-15
申请号：US18606764
申请日：2024-03-15
Applicant: Immatics Biotechnologies GmbH
Inventor： Ricarda HANNEN , Jens HUKELMANN , Florian KOEHLER , Daniel Johannes KOWALEWSKI , Heiko SCHUSTER , Oliver SCHOOR , Michael ROEMER , Chih-Chiang TSOU , Jens FRITSCHE
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/47 , C12N5/0783
CPC classification number: A61K35/17 , A61K39/0011 , A61P35/00 , C07K14/4748 , C12N5/0636
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240166717A1
公开(公告)日：2024-05-23
申请号：US18433940
申请日：2024-02-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC: C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC classification number: C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240166713A1
公开(公告)日：2024-05-23
申请号：US18433894
申请日：2024-02-06
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC: C07K14/725 , A61K35/17 , A61K38/00 , C07K14/74 , C07K16/28
CPC classification number: C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240158460A1
公开(公告)日：2024-05-16
申请号：US18421968
申请日：2024-01-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens HUKELMANN , Heiko SCHUSTER , Lena WULLKOPF , Christoph SCHRAEDER , Jens FRITSCHE , Daniel Johannes KOWALEWSKI , Michael ROEMER , Oliver SCHOOR
IPC: C07K14/725 , A61K35/17 , C07K14/74 , C07K16/28
CPC classification number: C07K14/7051 , A61K35/17 , C07K14/70539 , C07K16/2833 , A61K38/00 , C07K2319/30
Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
234
records
(took 0.023 seconds)
